AllAnalyst Report
Morningstar•March 27, 2024
Morningstar•March 27, 2024LivaNova PLC: LivaNova's Exit From Advanced Circulatory Support Leaves Focus on Its Two Principal Businesses
Summary
UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valv
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Intuitive Surgical IncApr 25, 2024 •
ISRG
- Market Update: CMG, ISRG, MAT, NOKApr 25, 2024 •
MAT, NOK, CMG, ISRG
- Analyst Report: Boston Scientific CorporationApr 24, 2024 •
BSX
- Analyst Report: Thermo Fisher Scientific Inc.Apr 24, 2024 •
TMO
- EW: Lowering target price to $92.00Apr 24, 2024 •
EW
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.